Skip to main content

Caracterización multimodal de las etapas prodrómicas del espectro Alzheimer-Lewy

PI22/00611

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

  • Verberk, I.M.W.
  • Jutte, J.
  • Kingma, M.Y.
  • Vigneswaran, S.
  • Gouda, M.M.T.E.E.
  • van Engelen, M.P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Chevalier, C.
  • Marizzoni, M.
  • van de Giessen, E.M.
  • Lemstra, A.W.
  • Pijnenburg, Y.A.L.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • den Braber, A.
  • Wilson, D.
  • Schut, M.C.
  • van Harten, A.C.
  • Teunissen, C.E.
INTRODUCTION: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS: We measured the plasma biomarkers with Simoa (n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach. RESULTS: P-tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre-dementia stages, AUC = 87%-89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%-76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand-alone biomarker results and density plots to visualize the biomarker results combined. DISCUSSION: Our multimarker blood test interpretation tool is ready for testing in real-world clinical dementia settings. Highlights: We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P-tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease

  • Bernhardt, Alexander Maximilian
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Longen, Sebastian
  • Trossbach, Svenja Verena
  • Giese, Armin
  • Matthias, Torsten
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Sanjuan, Aída
  • Fernández, Susana|||0000-0002-9777-1156
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Nübling, Georg|||0000-0003-4492-7302
  • Wagemann, Olivia
  • Stockbauer, Anna
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Fortea, Juan|||0000-0002-1340-638X
  • Levin, Johannes|||0000-0001-5092-4306
Alpha-synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome-associated Alzheimer's disease (DSAD). We analyzed αSyn-SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1-42/1-40, CSF and plasma p-Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP). ΑSyn-SAA was positive in 9.2% of cases, independent of age or cognitive status. Symptomatic αSyn-positive cases exhibited higher plasma NfL levels than αSyn-negative cases (31 vs 21 pg/mL, p = 0.027). LBP was observed in 47% of necropsies. The individual with severe neocortical LBP was αSyn-SAA-positive. These findings highlight LBP prevalence in DSAD but suggest current SAA may fail to detect limited αSyn deposition.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Novel Splicing Variant in Atypical Presentation of Familial Frontotemporal Lobar Degeneration

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Bernal, Sara|||0000-0003-4427-0574
  • Almenta Gallego, David|||0000-0001-9069-8948
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Camacho, Valle|||0000-0003-0748-0847
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
C-truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice-site variant (c.35-1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who presented at ages 62 and 66 years with a slowly progressive behavioral variant of frontotemporal dementia and a syndrome mimicking dementia with Lewy bodies, respectively. Functional and in silico analyses supported the pathogenicity of this variant. Our findings contribute new insights into the genetic landscape and clinical heterogeneity of FTLD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

  • Bolsewig, K.
  • Willemse, E.A.J.
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Rábano, Alberto|||0000-0001-9320-6566
  • Martínez, Minerva|||0000-0002-9036-2595
  • Doecke, J.D.|||0000-0003-2863-0293
  • Bellomo, Giovanni|||0000-0003-0456-5650
  • Vermunt, L.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Halbgebauer, S.
  • in 't Veld, S.
  • Mattsson-Carlgren, N.
  • Veverova, K.
  • Fowler, C.J.
  • Boonkamp, L.
  • Koel-Simmelink, M.
  • Hussainali, Z.
  • Ruiters, D.N.
  • Gaetani, L.
  • Toja, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Pijnenburg, Y.
  • Lemstra, A.W.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Hort, J.
  • Otto, M.|||0000-0003-4273-4267
  • Hansson, Oskar|||0000-0001-8467-7286
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Masters, C.L.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Teunissen, C.E.
  • Campo Milán, Marta del|||0000-0003-2808-3699
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in and

  • Gonzalez, Maria Camila|||0000-0003-1061-4164
  • Oftedal, Linn
  • Lange, Johannes
  • Tovar-Rios, Diego Alejandro
  • Tysnes, Ole-Bjørn
  • Paquet, Claire|||0000-0002-2273-7316
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Rejdak, Konrad
  • Papuc, Ewa
  • Hort, Jakub|||0000-0002-1080-3726
  • Falup-Pecurariu, Cristian
  • Aarsland, Dag|||0000-0001-6314-216X
  • Alves, Guido
  • Maple-Grødem, Jodi
Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid-beta 42 (Aβ42) levels, may hold potential as predictive indicators, providing valuable insights into the likelihood of cognitive decline within these diagnoses. Our objective was to determine their association with cognitive decline in DLB and PD. A total of 121 DLB patients from the European-DLB Consortium and 117 PD patients from the Norwegian ParkWest Study were included in this study. The four most commonly associated variants of GBA1 mutations (E326K, T369M, N370S, L444P), APOEε4 status, and cerebrospinal fluid (CSF) Aβ42 levels and GCase activity were assessed, as well as global cognition using the Mini-Mental State Examination. Linear mixed-effects regression models were used to evaluate the association of CSF biomarkers with cognitive decline in each diagnostic group, adjusted for age, sex, education, and genetic mutation profile. Low CSF Aβ42 levels were associated with accelerated cognitive decline in DLB, whereas reduced CSF GCase activity predicted faster cognitive decline in PD. These associations were independent of GBA1 gene mutations or APOEε4 status. Our study provides important evidence on the relationship between brain Aβ deposition and GCase activity in the Lewy body disease spectrum independent of their genetic mutation profile. This information could be relevant for designing future clinical trials targeting these pathways.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Busto, G.
  • Gabelle, A.
  • Ayrignac, X.
  • Bennys, K.
  • Muiño, Elena|||0000-0001-5839-7328
  • Villatoro-González, Paula|||0009-0001-0287-4073
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Pradeilles, N.
  • Bounasri, Shaima El
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Hirtz, C.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Lehmann, Sylvain|||0000-0001-6117-562X
Background: Blood-based assays are expected to be integrated into clinical routines across various contexts, including Alzheimer's disease (AD). Vascular dementia (VaD), which is the second most common cause leading to dementia after AD, could also significantly benefit from this advancement. However, no informative fluid biomarker has been identified for VaD. Given the disruption of iron homeostasis in both AD and VaD, this study aims to characterize the potential of the iron-related hormone Hepcidin as a biomarker for these two conditions. We will compare its added value to established AT(N) blood biomarkers. Methods: Blood biomarkers (amyloid-composite, p-Tau, Neurofilament Light Chain [NfL] and Hepcidin) levels in blood were analyzed in two independent cohorts and compared between AD patients and non-AD individuals. Additionally, blood Hepcidin and NfL were evaluated in the contexts of VaD and CADASIL, with their relative diagnostic value assessed. Results: Blood Hepcidin and NfL do not significantly increase the AUC obtained with both p-Tau and amyloid composite in the context of AD. In contrast, AUC for VaD diagnosis is significantly higher when combining these two blood biomarkers compared to NfL alone. Hepcidin was not significantly modified in CADASIL patients compared to control subjects. Conclusion: Blood Hepcidin and NfL have limited interest in the clinical context of AD but determination of these biomarkers shows to be highly informative for the diagnosis of VaD. This result could have important implications for diagnosis and implementation of clinical trials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers

  • Cervantes González, Alba|||0000-0003-1006-6719
  • Goossens, J.
  • Campuzano, E.V.
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Lidón Gil, Laia|||0000-0002-2083-3515
  • Perlaza, D.
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Haapasalo, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Vanmechelen, E.
  • Belbin, Olivia|||0000-0002-6109-6371
Background: Synaptic protein levels in cerebrospinal fluid (CSF) may represent much-needed objective biomarkers of cognitive impairment, disease progression and drug efficacy in patients with dementia with Lewy bodies (DLB). Soluble N-ethylmaleimide-sensitive factor attachment proteins receptors (SNARE) proteins, such as VAMP-2 and SNAP-25, are implicated in α-synuclein pathophysiology and CSF levels of these proteins are associated with pathophysiological biomarkers and cognitive decline in Alzheimer's disease (AD). The aim of the study was to compare CSF levels of VAMP-2 and SNAP-25 in patients with DLB to cognitively unimpaired controls and AD patients and study their association with cognitive performance and AD and neurodegeneration biomarkers. Methods: VAMP-2 and SNAP-25 were quantified in CSF from cognitively normal controls (n = 62), DLB (n = 44) and AD (n = 114) patients from the Sant Pau Initiative for Neurodegeneration (SPIN) cohort using homebrew Single Molecule Array assays (Simoa). The DLB group was stratified into two groups with ("DLB + AD", n = 28) or without AD co-pathology ("pure DLB", n = 16) using our validated cut-off for the CSF phosphorylated tau (p-tau)/Aβ42 ratio. We used linear regression to test for group differences (adjusting for age) and association with AD biomarkers. We used standardized w-scores of the cognitive tests to analyze the association of the synaptic markers with cognitive performance. Results: CSF VAMP-2 and SNAP-25 levels correlated across all groups (r = 0.71-0.9, p < 0.001). Both proteins were decreased in pure DLB (p < 0.001, p = 0.01) but increased in DLB + AD (p = 0.01, p = 0.02) compared to controls and showed good accuracy to discriminate pure DLB from DLB + AD (AUC = 0.84, 0.85). Both proteins were associated with CSF p-tau and total tau (t-tau) across all groups (r = 0.49-0.88, p < 0.001), with the Aβ42/40 ratio in DLB + AD (r = 0.29-0.36, p < 0.001) and in AD (r = 0.12-0.23, p < 0.001) and with CSF neurofilament-light chain (NfL) in controls (r²=0.10-0.11, p < 0.001-0.01) and AD patients (r²=0.01-0.08, p = 0.01 - 0.001). SNAP-25 was associated with CSF NfL in the DLB + AD group (r²=0.15, p = 0.02). CSF VAMP-2 and SNAP-25 were associated with phonemic fluency in pure DLB (r = 0.39 - 0.28, p = 0.01-0.03) and SNAP-25 with the Clock drawing test and the MMSE in DLB + AD (adj.r = 0.15 - 0.14, p = 0.03-0.03) and DLB (adj.r = 0.12 - 0.08, p = 0.02-0.04) groups. Conclusions: CSF VAMP-2 and SNAP-25 are promising surrogate markers of synapse degeneration in DLB. However, care should be taken when interpreting CSF levels of these synaptic markers in DLB in light of the confounding effect of AD pathophysiological markers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sleep-related changes in astrocytic biomarkers are modulated by APOE ε4 genotype in cognitively unimpaired adults

  • Zhu, Nuole|||0000-0002-0015-9455
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Carreras-Vega, Mireia
  • Romero, Sergio
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Giménez, Sandra|||0000-0001-8031-2319
  • Alcolea, Daniel|||0000-0002-3819-3245
Astrocytes are key regulators of sleep and neuroinflammatory responses. However, the relationship between objective sleep parameters and astrocytic fluid biomarkers in cognitively unimpaired individuals remains unclear. We examined how sleep architecture relates to astrocytic, neuroaxonal and Alzheimer's disease-related fluid biomarkers in cognitively unimpaired adults, and whether age, sex and APOE ε4 moderate these associations. This cross-sectional study included 51 cognitively unimpaired participants from the Sant Pau Initiative on Neurodegeneration cohort. One-night in-lab polysomnography was used to quantify sleep architecture, fragmentation, slow-wave activity, and respiratory parameters. CSF biomarkers included glial fibrillary acidic protein (GFAP), chitinase-like-3 protein 1 (YKL-40), Aβ42, Aβ40, pTau181, and tTau; plasma biomarkers included GFAP and neurofilament light chain (NfL). Associations were analyzed using Spearman correlations, multiple linear regression, and moderation models, adjusting for age, sex, body mass index, APOE ε4 status, and sleep apnea. Lighter and more fragmented sleep, characterized by longer N1 duration, increased wake after sleep onset, frequent stage transitions, and elevated cortical arousal, was associated with higher CSF YKL-40, Aβ40, pTau181 and tTau (rho = 0.32 to 0.62, all p<0.05). In contrast, deeper, more consolidated sleep, indicated by longer total time of sleep, greater N3 duration, and higher slow-wave activity, was associated with lower CSF GFAP and YKL-40 (rho = -0.35 to -0.44, all p<0.05). These associations remained significant in adjusted regression models. Plasma GFAP and NfL exhibited an inverse profile, with positive associations with deeper sleep (β: 0.16 to 0.18, p < 0.05) and negative associations with lighter sleep stages (β: -0.23 to -0.29, p < 0.01). REM sleep was also associated with astrocytic fluid biomarkers, with negative correlations for CSF and plasma GFAP (rho = -0.49 and rho = -0.28, respectively, all p<0.05), while in regression models REM duration remained a negative predictor of plasma GFAP (β = -0.23, p = 0.003) and a positive predictor of CSF YKL-40 (β = 0.12, p = 0.037). Notably, APOE ε4 consistently moderated associations between sleep and CSF YKL-40 and GFAP, while age and sex influenced plasma GFAP and CSF YKL-40, respectively (all p<0.05). In cognitively unimpaired adults, sleep architecture is differentially associated with central and peripheral biomarkers of astrocytic activation, neuroaxonal integrity and Alzheimer's disease-related proteins. These findings support the importance of considering sleep as a key factor in the early pathophysiology of neurodegenerative disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome

  • Sauer, M.
  • Gomes, B.F.
  • Shahrouki, P.
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Camporesi, E.
  • Belbin, Olivia|||0000-0002-6109-6371
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Kumar, A.
  • Sharma, M.
  • Singh, S.
  • Brinkmalm, G.
  • Gobom, J.
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Schöll, M.
  • Janelidze, S.
  • Deep, G.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Brinkmalm, A.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Hansson, Oskar|||0000-0001-8467-7286
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Nilsson, J.
INTRODUCTION: Synaptic dysfunction and loss are pathological hallmarks of neurodegenerative diseases. Neuronal pentraxin 2 (NPTX2), a presynaptic protein involved in synaptic plasticity, has been linked to cognitive decline in Alzheimer's disease (AD) and other neurodegenerative disorders. METHODS: We developed and validated a novel single molecule array (Simoa) for NPTX2 in cerebrospinal fluid, which was evaluated in two independent cohorts. RESULTS: CSF NPTX2 concentration was lower (fold change [FC] 0.82, p < 0.01) in AD patients and Down syndrome individuals (FC 0.56, p < 0.001), compared with cognitively unimpaired patients (CU). It was also associated with Mini-Mental State Examination (MMSE) score (β = 2.51, p < 0.001), tau-PET (β = -0.21, p < 0.01), and cortical thickness (β = 0.08, p < 0.001). DISCUSSION: We describe the first assay for NPTX2 on the Simoa platform, where we continue to highlight the valuable addition of NPTX2 to routine diagnostics of suspected cognitive impairment in patients as it associates better with cognition than other, more established AD biomarkers. Highlights: Novel method validated for measuring CSF NPTX2 on semi-automated Simoa platform. Method validated for use in CSF, where it shows a significant decrease in both AD and DS patients. Associated with cognition, neurofibrillary tangles, and cortical thickness in AD patients. Associations with cognition are shown to be stronger than those of pTau and NFL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of amyloid-negative neuropsychological norms using GAMLSS

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Estanga, Ainara|||0000-0002-6616-314X
  • Ecay-Torres, Mirian|||0000-0001-7170-6180
  • de Luis, C.L.
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Castellví, Magdalena|||0000-0001-8769-9288
  • Pozueta, A.
  • García-Martínez, M.
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Lage, Carmen|||0000-0003-1703-121X
  • López-Garcia, Sara
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Balasa, Mircea|||0000-0002-1795-4228
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Tainta, Mikel|||0000-0003-0624-1211
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
INTRODUCTION: Recent research has suggested increased sensitivity of Alzheimer's disease (AD)-negative neuropsychological norms; concurrently, generalized additive models for location, scale, and shape (GAMLSS) have emerged as a promising alternative to traditional norming approaches. Here, we developed amyloid β-negative (Aβ-) next-generation norms (NGN) for a comprehensive neuropsychological battery using GAMLSS. METHODS: We included N = 987 cognitively normal (CN) individuals from a Spanish multicenter study with extensive neuropsychological data and cerebrospinal fluid AD biomarker assessment. NGN were developed using GAMLSS based on the performance of n = 774 Aβ- CN individuals aged 30-90 years. RESULTS: Age-, education-, and sex-adjusted z-scores were obtained for 14 measures covering the main cognitive domains (memory, language, attention/executive, and visuospatial functions). A user-friendly calculator for the z-scores was made available in an open-access ShinyApp to facilitate their application. DISCUSSION: NGN may improve the detection of objective cognitive impairment in clinical and research settings. Highlights: Brain amyloid β (Aβ) is associated with poorer performance in cognitively normal individuals. We provide GAMLSS-based Aβ-negative norms for 14 neuropsychological measures. Age, education, and often sex significantly influence cognitive performance. An online calculator for the demographically adjusted z-scores is freely available.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola-Infante, J.E.
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. Methods: We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A +) or negative (A-) according to CSF Aβ1-42/Aβ1-40 ratio. Plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ1-42/Aβ1-40 ratio. We analyzed the concordance of pTau217 with CSF amyloidosis. Results: Plasma pTau217 and pTau181 concentration were higher in A + than A- while the plasma Aβ1-42/Aβ1-40 ratio was lower in A + compared to A-. pTau181 and the Aβ1-42/Aβ1-40 ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau217, and 0.88 (95% CI 0.84-0.92) for both pTau181 and Aβ1-42/Aβ1-40. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau217 had the highest fold change (× 3.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau217 using a two-threshold approach was robust in symptomatic groups, exceeding 90%. Conclusion: The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau217 showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome

  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Aranha, Mateus|||0000-0001-9594-292X
  • Aragón, Irina
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, S.
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Hernandez, Aida S.
Background and Objectives Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers. Methods This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E (APOE) genotyping; fluid and plasma determinations of beta-amyloid, tau, and neurofilament light; cognitive outcomes (Cambridge Cognitive Examination and modified Cued Recall Test); and vascular risk factors (hypertension, diabetes mellitus, and dyslipidemia). We manually segmented microbleeds and characterized their topography. Associations between microbleed severity and AD biomarkers were explored using between-group comparisons (none vs 1 vs 2+) and multivariate linear models. Results We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%, p < 0.001), with more severe presentation (12% with 2+ vs 1.9%). Microbleeds increased with age (12% 20-30 years vs 60% > 60 years) and AD clinical stage (12.42% asymptomatic, 27.9% prodromal, 35.09% dementia) were more common in APOEe4 carriers (26% vs 18.3% noncarriers, p = 0.008), but not associated with vascular risk factors (p > 0.05). Microbleeds were predominantly posterior (cerebellum 33.66%; occipital 14.85%; temporal 21.29%) in participants with DS. Associations with microbleed severity were found for neuroimaging and fluid AD biomarkers, but only hippocampal volumes (standardized β = -0.18 [-0.31, -0.06], p < 0.005) and CSF p-tau-181 concentrations (β = 0.26 [0.12, 0.41], p < 0.005) survived regression controlling for age and disease stage, respectively. Microbleeds had limited effect on cognitive outcomes. Discussion In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome, A decade of discovery

  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Estellés, Teresa
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Sánchez-Aced, Érika|||0000-0001-7280-7493
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Muñoz, Laia|||0000-0003-0578-3094
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Sánchez López, Oriol|||0000-0001-9405-1236
  • Garzón, Diana
  • Ribas, Laia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Camacho, Valle|||0000-0003-0748-0847
  • Giménez, Sandra|||0000-0001-8031-2319
  • Delaby, Constance|||0000-0002-8606-6814
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla, Sebastià
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Carreras, Mireia
  • Lorente, Oriol
  • Bounasr El Bennadi, Shaima El
  • Elbachiri, Sumia
  • Mota, Cecilia
  • Iulita, M. Florencia|||0000-0002-3360-4498
Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42.82, 46.3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. Highlights: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients

  • Hok-A-Hin, Yanaika S.|||0000-0001-9713-116X
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Barkhof, Frederik|||0000-0003-3543-3706
  • del Campo, Marta
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Vermunt, Lisa
  • Oosthoek, Marlies
  • Vijverberg, Everard G.B.
  • Blujdea, Elena R.
  • Veld, Sjors G.J.G.In't
  • Pucheu Avilés, Martín
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Visser, Allerdien
  • Schut, Martijn C.
Background: Amyloid-related imaging abnormalities (ARIA) are a common and potentially dangerous side effect in anti-amyloid therapies, creating a need for tools to assess ARIA risk. Several patient factors have been linked to ARIA; namely the presence of microbleeds (MBL), APOE E4 carriership (APOE4), and extremely low CSF Aβ42 concentrations (A). We hypothesize that studying the CSF proteome of Alzheimer's disease (AD) dementia patients from a high-risk group (MBLAPOE4A) can inform on the biological underpinnings of ARIA risk and aid the progress of ARIA risk biomarkers. Methods: We utilized CSF proteomic data of AD (n = 156) and cognitively unimpaired individuals (CU n = 100) of the Amsterdam Dementia Cohort. The proteome of the defined high-risk (n = 13) was compared to low-risk AD group (n = 23), using age and sex corrected linear regressions followed by gene ontology analysis. For biomarker prioritization, we selected proteins that were abnormal in the high-risk group versus low-risk and CU patients. The biomarkers were validated in an independent cohort (high risk n = 14, low risk n = 9) analyzed using customized multiplex panels. Lastly, we assessed biomarker lead co-expression. Results: Ninety-four proteins differentiated in the high-risk group compared to low-risk (p < 0.05), none surviving FDR correction. These proteins were enriched for synapse-related proteins and axonogenesis. CHIT1 (vs. low-risk AD: FC = 1.0, p = 0.014, vs. CU: FC = 2.4, p < 0.001) and DDAH1 (vs. low-risk AD: FC=-0.31, p = 0.046, vs. CU: FC = 0.5, p < 0.001) were prioritized as biomarker. DDAH1 protein changes replicated in an independent cohort (FC=-0.37, p = 0.010), and CHIT1 replicated on a trend level (FC = 0.70, p = 0.104). DDAH1 levels had the highest co-expression with synaptic process, energy utilization and RNA-binding cell signaling related proteins (R > 0.8). Conclusions: The findings suggest that in the high risk group, there is a lack of upregulation in synapse and axonogenesis related proteins. High CSF CHIT1 and less increased CSF DDAH1 levels within AD relate to ARIA risk. From the literature, the link to ARIA risk for CHIT1 could be its contribution to innate immunity or vascular amyloid deposition, and for DDAH1 to blood-brain barrier integrity. Biomarker assays are available to assess the potential of CHIT1 and DDAH1 in trials and treatment studies in the clinical setting.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Study of brain perfusion in adults with Down Syndrome along the Alzheimer's Disease continuum

  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, Susana|||0000-0002-9777-1156
  • Hernandez, Aida Sanjuan
  • Giménez, Sandra|||0000-0001-8031-2319
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Bejanin, Alexandre|||0000-0002-9958-0951
Down Syndrome (DS) represents a high-risk group for Alzheimer's disease (AD) due to chromosome 21 triplication, which drives amyloid precursor protein overproduction. While brain atrophy in DS has been widely studied, the underlying brain perfusion changes remain poorly understood. This study leverages MRI pseudo-continuous arterial spin labeling (pCASL) to explore early cerebral blood flow (CBF) alterations along the AD continuum in DS and compares these changes to the perfusion patterns seen in sporadic AD (sAD) We performed a cross-sectional analysis including 32 euploid cognitively unimpaired individuals (eCU, age= 56.8yo, 68.7% female), 37 adults with DS (age= 42.64y; females= 37.83%, 40.5% symptomatic including n = 8 prodromal AD and n = 7 dementia) and 24 sAD patients (age 74.2yo, 50% female, 16 MCI and 8 in dementia stage) from the SPIN and DABNI cohorts that underwent 3T-MRI. pCASL images were preprocessed using ASLprep. Analyses explored the effects of demographic variables (age, sex), clinical stages, and AD biomarkers (including cerebrospinal fluid [CSF] Aβ1-42/Aβ1-40 ratio, pTau-181, and hippocampal volume) on global and regional CBF. Age-related decreases in cerebral blood flow (CBF) were observed in prefrontal regions in eCU, parietal structures in DS, and temporal lobes in sAD (Figure 1 A-D). Females had higher perfusion than males in eCU and sAD, but not in DS (Figure 1 E-H). In DS, CBF was reduced in temporal-parietal regions in asymptomatic individuals, extending to frontal areas in symptomatic cases, resembling sAD patterns (Figure 2). Symptomatic DS showed significantly lower CBF in lateral parietal regions than asymptomatic DS. Temporoparietal CBF correlated negatively with CSF-pTau-181 and positively with CSF-Aβ1-42/Aβ1-40 ratio and hippocampal volume, with the strongest association seen with hippocampal volume (Figure 3) Brain perfusion is significantly altered in adults with DS along the AD continuum, with changes detectable even before clinical symptoms. Hypoperfusion primarily affects temporoparietal and frontal regions at the symptomatic stage, closely resembling patterns seen in sAD. Notably, perfusion in the parietal areas differentiates asymptomatic from symptomatic DS and correlates strongly with key AD biomarkers. These findings highlight the potential of pCASL to detect early functional changes in this high-risk population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

  • Janelidze, Shorena
  • Therriault, Joseph
  • Brum, Wagner S.
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Stomrud, Erik
  • Palmqvist, Sebastian|||0000-0002-9267-1930
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Rahmouni, Nesrine
  • Gispert, Juan Domingo|||0000-0002-6155-0642
  • Blennow, Kaj|||0000-0002-1890-4193
  • Doré, Vincent
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Villeneuve, Sylvia
  • Johnson, Sterling C.
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Petersen, Ronald C.
  • Schindler, Suzanne E.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Ossenkoppele, Rik
  • Hansson, Oskar|||0000-0001-8467-7286
  • Salvadó, Gemma
  • Bali, Divya
  • Orduña Dolado, Anna
  • Mattsson-Carlgren, Niklas
  • Coomans, Emma M.
  • Benzinger, Tammie L. S.
  • Feizpour, Azadeh
  • Rowe, Christopher C.
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ϵ4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P =.12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P <.001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P <.001). Conclusions and Relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test - or when used in a sequential 2-step approach alongside PET or CSF testing - as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments..
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old

  • Ceriello, Chiara
  • Torres Bonafonte, Olga H.|||0000-0002-0305-8211
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Vera-Campuzano, Elena
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Lorente, Oriol
  • Carreras, Mireia
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Background and Objectives: Alzheimer disease (AD) is increasingly viewed as a clinical-biological continuum, but the utility of biomarkers in individuals aged ≥80 years, the so-called “very old,” remains uncertain, because of concerns about its clinical usefulness. This study aimed to determine the clinical impact and prognostic value of AD biomarkers in very old individuals. Methods: We performed a retrospective longitudinal cohort study within the Sant Pau Initiative on Neurodegeneration (SPIN, Barcelona, Spain), a memory clinic–based research cohort. Patients were referred from primary care physicians or community neurologists for evaluation within a public universal health care catchment area. We included SPIN participants evaluated between October 2013 and May 2024 who were aged ≥80 years and had mild cognitive impairment (MCI) at the baseline visit. Participants underwent standardized clinical and neuropsychological assessments and had CSF and plasma biomarker measurements available. AD biology was defined by the CSF phosphorylated tau at threonine 181/amyloid-β 42 ratio. Plasma phosphorylated tau at threonine 217 (p-Tau217) was evaluated for (1) diagnostic accuracy for AD biology and (2) prognostic associations with longitudinal cognitive change (Mini-Mental State Examination [MMSE]) and progression to dementia. Analyses used linear mixed-effects models for MMSE trajectories and Cox regression for dementia conversion. Results: A total of 167 participants were included (mean age 82.3 years, 59% women) with a mean follow-up of 35.8 months; the ones with AD biology (n = 116, 69%) had worse baseline cognitive performance, particularly in memory, compared with those without (Cohen d = 0.34, p = 0.03). Plasma p-Tau217 showed excellent diagnostic accuracy for detecting AD biology (0.93, 95% CI 0.88–0.98; cutoff 0.19 pg/mL; sensitivity 94.5%; specificity 84%). Over time, participants with AD biology declined faster on the MMSE than those without (−0.47 vs −0.18 points per year; p < 0.01). Cox models showed an increased risk of progression to a dementia stage among individuals with higher plasma p-Tau217 concentrations (hazard ratio 1.49, 95% CI 1.05–2.13, p = 0.026). Discussion: In very old individuals with MCI, AD biology (CSF) and plasma p-Tau217 identify individuals at higher risk of faster cognitive decline and progression to dementia. Limitations of this study include the single-center design and the modest sample size.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

  • Chatterjee, Madhurima
  • Özdemir, Selcuk
  • Fritz, Christian
  • Möbius, Wiebke|||0000-0002-2902-7165
  • Kleineidam, Luca
  • Mandelkow, Eckhard|||0000-0003-4655-4829
  • Biernat, Jacek
  • Doğdu, Cem
  • Peters, Oliver|||0000-0003-0568-2998
  • Cosma, Nicoleta Carmen|||0000-0002-2656-8046
  • Wang, Xiao
  • Schneider, Luisa-Sophia
  • Priller, Josef|||0000-0001-7596-0979
  • Spruth, Eike
  • Kühn, Andrea A.|||0000-0002-4134-9060
  • Krause, Patricia
  • Klockgether, Thomas
  • Vogt, Ina R.
  • Kimmich, Okka
  • Spottke, Annika
  • Hoffmann, Daniel C.
  • Fliessbach, Klaus
  • Miklitz, Carolin
  • McCormick, Cornelia
  • Weydt, Patrick
  • Falkenburger, Björn
  • Brandt, Moritz
  • Guenther, René
  • Dinter, Elisabeth
  • Wiltfang, Jens
  • Hansen, Niels
  • Bähr, Mathias
  • Zerr, Inga
  • Flöel, Agnes
  • Nestor, Peter J.
  • Düzel, Emrah
  • Glanz, Wenzel
  • Incesoy, Enise
  • Bürger, Katharina
  • Janowitz, Daniel
  • Perneczky, Robert|||0000-0003-1981-7435
  • Rauchmann, Boris S.
  • Hopfner, Franziska
  • Wagemann, Olivia
  • Levin, Johannes|||0000-0001-5092-4306
  • Teipel, Stefan
  • Kilimann, Ingo
  • Goerss, Doreen
  • Prudlo, Johannes
  • Gasser, Thomas|||0000-0003-4882-2647
  • Brockmann, Kathrin|||0000-0002-7515-8596
  • Mengel, David
  • Zimmermann, Milan
  • Synofzik, Matthis|||0000-0002-2280-7273
  • Wilke, Carlo
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Fortea, Juan|||0000-0002-1340-638X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Lleó, Alberto|||0000-0002-2568-5478
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Wagner, Michael
  • Frommann, Ingo|||0000-0002-7244-2014
  • Roeske, Sandra|||0000-0002-8262-4356
  • Bertram, Lucas
  • Heneka, Michael|||0000-0003-4996-1630
  • Brosseron, Frederic
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Schmid, Matthias
  • Beschorner, Rudi
  • Halle, Annett
  • Herms, Jochen
  • Neumann, Manuela
  • Barthélemy, Nicolas R.
  • Bateman, Randall|||0000-0002-7729-1702
  • Rizzu, Patrizia
  • Heutink, Peter|||0000-0001-5218-1737
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Höglinger, Günter|||0000-0001-7587-6187
  • Hermann, Andreas|||0000-0002-7364-7791
  • Schneider, Anja|||0000-0001-9540-8700
Minimally invasive biomarkers are urgently needed to detect molecular pathology in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Here, we show that plasma extracellular vesicles (EVs) contain quantifiable amounts of TDP-43 and full-length tau, which allow the quantification of 3-repeat (3R) and 4-repeat (4R) tau isoforms. Plasma EV TDP-43 levels and EV 3R/4R tau ratios were determined in a cohort of 704 patients, including 37 genetically and 31 neuropathologically proven cases. Diagnostic groups comprised patients with TDP-43 proteinopathy ALS, 4R tauopathy progressive supranuclear palsy, behavior variant FTD (bvFTD) as a group with either tau or TDP-43 pathology, and healthy controls. EV tau ratios were low in progressive supranuclear palsy and high in bvFTD with tau pathology. EV TDP-43 levels were high in ALS and in bvFTD with TDP-43 pathology. Both markers discriminated between the diagnostic groups with area under the curve values.